|
|
|||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
The editors asked two members of the President's Council on Bioethics to address the following questions:
Research on human embryonic stem cells holds great promise for the development of therapies for chronic and debilitating diseases that are currently untreatable. Should the federal government of the United States provide funding for such research? If it does not provide such funding but effective stemcell-based therapies are developed elsewhere, should their use be allowed in the United States?
Michael J. Sandel, D.Phil., is the Anne T. and Robert M. Bass Professor of Government at Harvard University. Paul McHugh, M.D., is the Henry Phipps
Source Information
From the Department of Government, Harvard University, Cambridge, Mass.
Related Letters:
Ethics of Embryonic Stem Cells
George R. P., Lee P., Kay G. N., Pullicino P. M., Anderson R. E., Erickson C. P., Levick S. E., Sandel M. J., McHugh P.
Extract |
Full Text |
PDF
N Engl J Med 2004;
351:1687-1690, Oct 14, 2004.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |